The Fight Against Diabetes
47 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Mary Starry
Scoop.it!

GLP-1 receptor agonists: why is once weekly inferior to once daily? : The Lancet Diabetes & Endocrinology

GLP-1 receptor agonists: why is once weekly inferior to once daily?. By - Alan J Garber
Mary Starry's insight:

The longer acting GLP-1 receptor agonists both seem to have decreased GI side effects, but also seem to have decreased efficacy.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Amino Acid's Increase Is Suspected In Diabetes - Science 2.0

Amino Acid's Increase Is Suspected In Diabetes
Science 2.0
SAN ANTONIO (Dec.
more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Gender Affects How Heart Reacts To Diabetes Medication - Health News - redOrbit

Gender Affects How Heart Reacts To Diabetes Medication - Health News - redOrbit | The Fight Against Diabetes | Scoop.it
In a new study, the type 2 diabetes drug metformin was found to have different effects on the hearts of men and women, despite managing blood sugar the same in both sexes.
Mary Starry's insight:

Metformin has always been looked at as beneficial in regards to cardiovascular risk for diabetes.  However this new research, which looks at what fuel the heart is using for energy, finds that metformin has beneficial impact on womens' hearts while shifting fuel use in mens' hearts to a less beneficial pattern.  We will need further studies to look indepth at this as corroboration will result in some shifts in metformin usage.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Metformin improves outcomes for cancer patients with type 2 diabetes

In cancer patients with concurrent type 2 diabetes, metformin alone or in combination with other regimens was associated with 34% reduction in overall death risk and 38% reduction in cancer-spe
Mary Starry's insight:

From this meta-analysis, cancer patients with diabetes who were taking metformin had a reduced risk of death from cancer compared to those not taking metformin. The lowest risk was seen in pancreatic and colorectal cancers.  Remember this is an association between metformin and risk of cancer death and does not tell us metformin cures cancer.  However, if you have both cancer and diabetes, metformin is always a good choice as one of your diabetes medications!

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

MannKind is seeking approval for diabetes inhaler system by spring

MannKind is seeking approval for diabetes inhaler system by spring | The Fight Against Diabetes | Scoop.it
MannKind Corp. in Valencia is attempting to revolutionize the treatment of Type 1 and Type 2 diabetes with its first product: an inhaled form of insulin powder called Afrezza that would eliminate the need for most injections.
Mary Starry's insight:

We may have an inhaled insulin back on the market! Afrezza has completed Phase III studies and is being reviewed by the FDA. Exubera, our previous inhaled insulin, was on the market for only a couple years before the manufacturer stopped production and pulled the product.

 

Afrezza will be designed to replace bolus insulin, or quick acting insulin, the same as Exubera was.  Patients would still need to take long acting insulins to meet their basal needs.  If Afrezza has truly overcome the biggest hurdle to Exubera, the large inhaler device, and meets FDA expectations, this may be a viable approach to insulin administration.

 

 

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Meter, smartphone app help diabetics monitor their glucose levels

Two U.S. firms are working on Bluetooth devices coupled with a smartphone app to allow diabetics to monitor their glucose levels more closely and accurately.
Mary Starry's insight:

The key to this will then be to have the information transferred to someone that has the time to analyze the data and provide input back to the patient.  Will there be reimbursement for that?

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

New data backs promise of long-acting Sanofi insulin

New data backs promise of long-acting Sanofi insulin | The Fight Against Diabetes | Scoop.it
PARIS (Reuters) - An improved version of Sanofi's diabetes drug Lantus is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed...
Mary Starry's insight:

Very interesting how more concentrated versions of current insulins provides a longer duration of action and a lower risk for hypoglycemia. I just hope they develop U300 insulin syringes or pens to match the insulin. U500 Regular has a huge risk potential when patients use U100 syringes to measure with.

 

Then the combination of insulin plus GLP-1 agonists seems to be the combination of the future from the new combination products being developed.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Studys

Mary Starry's insight:

I really dislike authors making claims about improved beta cell function in regards to diabetes medications when any improvement in glycemic control reduces glucose toxicity and improves beta cell function. If you want me to believe that your product improves beta cell function, show a significantly greater increase over what would have been obtained by another agent decreasing glucose levels a similar amount.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Diabetes: Insulin pumps in children with T1DM[mdash]we told you so : Article : Nature Reviews Endocrinology

Diabetes: Insulin pumps in children with T1DM[mdash]we told you so : Article : Nature Reviews Endocrinology | The Fight Against Diabetes | Scoop.it
Mary Starry's insight:

Ten years ago we were already moving towards getting all of our Type 1 children moved to insulin pumps.  Hard to believe some physicians still question their superiority.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Women Under 60 With Diabetes at Much Greater Risk for Heart Disease

Women Under 60 With Diabetes at Much Greater Risk for Heart Disease | The Fight Against Diabetes | Scoop.it
Generally, women under 60 are at far less risk for coronary artery disease than men of the same age. But among women of that age who have diabetes, their risk of heart disease increases by up to fo...
Mary Starry's insight:

Basically getting diabetes removes the benefit of being female!

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Medicare Annual Wellness Visit Benefit

Medicare Annual Wellness Visit Benefit | The Fight Against Diabetes | Scoop.it
Mary Starry's insight:

Make sure your patients with diabetes are aware of this health benefit.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Type 1 Diabetes Treatment Gets Stem Cell Makeover

Type 1 Diabetes Treatment Gets Stem Cell Makeover | The Fight Against Diabetes | Scoop.it
Scientists have developed a stem cell approach to treating type 1 diabetes through the conversion of skin cells into pancreas-like cells.
Mary Starry's insight:

Additional research looking at how to create stem cells for insulin production, this time from skin cells!

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Only half of at-risk adults being screened for diabetes : Clinical Endocrinology News

Only half of at-risk adults being screened for diabetes : Clinical Endocrinology News | The Fight Against Diabetes | Scoop.it
MELBOURNE – Approximately half of adults who meet the eligibility for glucose testing according to four different guidelines are not being tested for type 2 diabetes, according to data from a large survey of U.S.
Mary Starry's insight:

Find it hard to believe that only 1/2 of US population eligible for diabetes screening are actually being screened.  Since this was based on patient recall, I suspect that many people have had a glucose test on a comprehensive lab profile but were not aware their physician had the information.  Patient recall is not the best data.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

FDA approves the first generic versions of depression drug Cymbalta

FDA announced that it had given approval to several pharmaceutical companies to market duloxetine delayed-release capsules (Cymbalta, Eli Lilly), for the treatment of depression and other conditions
Mary Starry's insight:

Cymbalta is often used by persons with diabetes to treat painful neuropathy symptoms as well as for depression.  Having generic versions available will make this medication more accessible to patients.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

FDA panel backs Bristol diabetes drug after prior rejection

Dec 12 (Reuters) - By a lopsided vote of 13 to 1, anindependent committee of medical experts on Thursday voted torecommend approval of a new type of diabetes drug fromBristol-Myers Squibb that U.S.
Mary Starry's insight:

The second SGLT-2 receptor blocker to be approved in the United States. I still struggle with the concept of prescribing a medication that does not work on one of the primary defects causing diabetes, but instead uses a symptom to lower hyperglycemia. 

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Pancreatic Risks No Greater With Victoza

Pancreatic Risks No Greater With Victoza | The Fight Against Diabetes | Scoop.it
The treatment of type 2 diabetes with liraglutide (Victoza) didn't lead to an increased rate of acute pancreatitis or pancreatic cancer compared with other anti-diabetic drugs, an interim analysis sug...
Mary Starry's insight:

Recent research published in Diabetes, Obesity and Metabolism found no higher incidence of pancreatitis or pancreatic cancer associated with liraglutide than with metformin, sulfonylureas or pioglitazone.

more...
No comment yet.
Rescooped by Mary Starry from Educational Technology News
Scoop.it!

5 Techniques To Encourage Students to Consume Flipped or Blended Learning Content

5 Techniques To Encourage Students to Consume Flipped or Blended Learning Content | The Fight Against Diabetes | Scoop.it

"One question that usually arises in most discussions about flipped teaching is, “How can I help ensure that students will watch or listen to the learning?"


Via EDTECH@UTRGV
Mary Starry's insight:

Some good suggestions for how to encourage students to view videos or read articles you've assigned prior to class.  I've mainly used the quiz approach, but want to start trying some worksheets to help students focus on the key points in the videos or readings.

more...
Scooped by Mary Starry
Scoop.it!

FDA Approves NovoLog FlexTouch and Levemir FlexTouch

FDA Approves NovoLog FlexTouch and Levemir FlexTouch | The Fight Against Diabetes | Scoop.it
Novo Nordisk announced that the FDA has approved NovoLog insulin aspart rDNA origin injection FlexTouch and Levemir insulin detemir rDNA origin injection FlexTouch, its two new prefilled insulin delivery systems.
Mary Starry's insight:

These new pens do not have the button extend out as far with larger doses, making it easier to administer higher insulin dosages.

more...
No comment yet.
Scooped by Mary Starry
Scoop.it!

Dual-Agonist Compound Promising in T2D, Obesity - MedPage Today

Dual-Agonist Compound Promising in T2D, Obesity - MedPage Today | The Fight Against Diabetes | Scoop.it
Dual-Agonist Compound Promising in T2D, Obesity
MedPage Today
The three drugs had comparable effects on food intake, hyperglycemia, and dyslipidemia, researchers reported.
Mary Starry's insight:

Still in early stages of development, but a class to keep an eye on to see if research continues.

more...
No comment yet.
Rescooped by Mary Starry from Stem Cells & Tissue Engineering
Scoop.it!

Mini-pancreas grown from stem cells has implications for future insulin delivery

Mini-pancreas grown from stem cells has implications for future insulin delivery | The Fight Against Diabetes | Scoop.it

Via Jacob Blumenthal
more...
Jacob Blumenthal's curator insight, October 16, 2013 2:02 AM

In a paper, published in Development journal, researchers from the  Danish Stem Cell Centre have shown that they can culture mouse pancreatic cells into expanded, branched structures in a 3D culture.

By manipulating the medium composition they  generated either hollow spheres, which are mainly composed of pancreatic progenitors, or complex organoids that spontaneously undergo pancreatic morphogenesis and differentiation.

Manipulation and improvement of  culture and expansion techniques 

 could lead to a more efficient and  developed method of creating insulin-releasing beta cells, which will eventually be used for cell therapy of diabetes.

http://dev.biologists.org/content/140/21/4452.full

 

To learn about pancreatic development:

http://discovery.lifemapsc.com/in-vivo-development/pancreas

 

To learn about stem cells differentiation protocols:

http://discovery.lifemapsc.com/stem-cell-differentiation/protocols

 

 

Carlos Garcia Pando's curator insight, October 16, 2013 2:04 PM

Another wonder result from tissue engineering!